Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Concordance between criteria for covariate model building.

Hennig S, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):109-25. doi: 10.1007/s10928-014-9350-8. Epub 2014 Mar 6.

PMID:
24599695
2.

A reduction in between subject variability is not mandatory for selecting a new covariate.

Lagishetty CV, Vajjah P, Duffull SB.

J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):383-92. doi: 10.1007/s10928-012-9256-2. Epub 2012 Jul 6.

PMID:
22767340
3.

Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Wählby U, Thomson AH, Milligan PA, Karlsson MO.

Br J Clin Pharmacol. 2004 Oct;58(4):367-77.

4.

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.

Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR.

J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):393-414. doi: 10.1007/s10928-012-9258-0. Epub 2012 Jul 6.

5.

The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.

Tunblad K, Lindbom L, McFadyen L, Jonsson EN, Marshall S, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):503-26. doi: 10.1007/s10928-008-9099-z. Epub 2008 Nov 15.

PMID:
19011957
6.

Use of a linearization approximation facilitating stochastic model building.

Svensson EM, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):153-8. doi: 10.1007/s10928-014-9353-5. Epub 2014 Mar 13.

7.

Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.

Dosne AG, Bergstrand M, Harling K, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596. Epub 2016 Oct 11.

8.

Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Ribbing J, Jonsson EN.

J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34.

PMID:
15379381
9.

Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.

Bruno R, Iliadis MC, Lacarelle B, Cosson V, Mandema JW, Le Roux Y, Montay G, Durand A, Ballereau M, Alasia M, et al.

J Pharmacokinet Biopharm. 1992 Dec;20(6):653-69.

PMID:
1302767
10.

Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Joerger M.

AAPS J. 2012 Mar;14(1):119-32. doi: 10.1208/s12248-012-9320-2. Epub 2012 Jan 25. Review.

11.

A fast method for testing covariates in population PK/PD Models.

Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO.

AAPS J. 2011 Sep;13(3):464-72. doi: 10.1208/s12248-011-9289-2. Epub 2011 Jul 2.

12.

Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH.

Br J Clin Pharmacol. 2007 Jan;63(1):75-84. Epub 2006 Jul 21.

13.

Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Wählby U, Matolcsi K, Karlsson MO, Jonsson EN.

J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):61-74.

PMID:
15346852
14.

An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis.

Yamashita F, Fujita A, Sasa Y, Higuchi Y, Tsuda M, Hashida M.

J Pharm Sci. 2017 Sep;106(9):2407-2411. doi: 10.1016/j.xphs.2017.04.029. Epub 2017 Apr 25.

PMID:
28450239
15.

Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Mandema JW, Verotta D, Sheiner LB.

J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28.

PMID:
1287200
16.

Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

Blair EY, Rivory LP, Clarke SJ, McLachlan AJ.

Br J Clin Pharmacol. 2004 Apr;57(4):416-26.

17.

Design of pharmacokinetic studies for latent covariates.

Lagishetty CV, Coulter CV, Duffull SB.

J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):87-97. doi: 10.1007/s10928-011-9231-3. Epub 2011 Dec 10.

PMID:
22161222
18.
19.

Implications of choosing a correlation structure on model selection and parameter estimation.

Jain L, Jadhav P, Gobburu J.

Int J Clin Pharmacol Ther. 2014 Jul;52(7):598-611. doi: 10.5414/CP202058.

PMID:
24725444
20.

dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.

Dosne AG, Niebecker R, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):597-608. Epub 2016 Oct 11.

Supplemental Content

Support Center